Background
==========

IVIg is a polyclonal IgG preparation with potent immune-modulating properties. We demonstrated that IVIg protects against airway hyperreactivity (AHR) and airway inflammation in mouse models of allergic airway disease, accompanied by peripheral induction of Foxp3^+^regulatory T-cells (iT~reg~). The requirement of IVIg-induced iT~reg~ and their antigen-specificity in attenuation of AHR and airway inflammation remains unknown.

Methods
=======

We utilized DEREG mice, carrying a transgenic diphtheria toxin receptor under the control of the Foxp3 promoter, allowing for selective depletion of Foxp3^+^T~reg~ by the application of diphtheria toxin (DT). Mice were sensitized and challenged with ovalbumin (OVA) and treated with IVIg. AHR was measured using a FlexiVent small animal ventilator. Total and antigen-specific IgE, as well as pro-inflammatory cytokines levels were determined in serum and alveolar lavage, using ELISA.

Results
=======

In the absence of Treg, due to multiple DT doses before and after the treatment, IVIg was not able to attenuate AHR, diminish IgE levels and Th-2 type cytokine production, nor alleviate airway inflammation. However, mice in which the pre-established T~reg~ cells (nT~reg~) were depleted before but not following IVIg treatment demonstrated an induction of Foxp3^+^T~reg~ to IVIg therapy and did not develop AHR and airway inflammation to allergen-challenge. Adoptive transfer of enriched IVIg-induced iT~reg~ from OVA-IVIg treated mice failed to transfer protection to mice exposed to ragweed, but was protective in OVA-sensitized and challenged mice.

Conclusions
===========

T~reg~ can be induced from effector CD4^+^T-cells in the absence of nT~reg~. IVIg-induced antigen specific T~reg~ are capable of suppressing all aspects of antigen-driven airway inflammation in an antigen-specific manner.
